Drug Approval | November 08, 2023
Lupin receives USFDA tentative approval for Canagliflozin and Metformin Hydrochloride ER Tablets
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin’s Pithampur facility in India
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
The company expects that this development could improve the strength of its application to the FDA for new drug approval
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Lupin enters into BTA with Lupin Manufacturing Solutions
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Lokavant provides clinical trial intelligence
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
Subscribe To Our Newsletter & Stay Updated
